

# Experimental Chemotherapy-induced Skin Necrosis in Swine

## Mechanistic Studies of Anthracycline Antibiotic Toxicity and Protection with a Radical Dimer Compound

Steven D. Averbuch, Marybeth Boldt,\* Giorgio Gaudiano,\* Jere B. Stern, Tad H. Koch,\* and Nicholas R. Bachur

Laboratory of Biological Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; \*Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215

### Abstract

The reactivity of antitumor anthracycline and mitomycin C antibiotics with the oxomorpholinyl radical dimers, bi(3,5,5-trimethyl-2-oxomorpholin-3-yl) (TM3) and bi(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl) (DHM3), was studied *in vitro*. The oxomorpholinyl radical reduced daunorubicin to a quinone methide intermediate that reacted with solvent to form 7-deoxydaunorubicinone. The solvolysis reaction followed first order kinetics, and the reactivity rate constants ( $k_2$ ) measured for seven anthracycline analogues ranged from  $2 \times 10^{-2} \text{ s}^{-1}$  to  $8.0 \times 10^{-4} \text{ s}^{-1}$ . The chemical reactivity of each anthracycline quinone methide correlated with the total skin toxicity caused by the respective parent anthracycline following injection into swine skin.

Microscopic examination of experimental lesions in swine skin resemble those observed in humans after inadvertent chemotherapy extravasation. Hydrocortisone sodium succinate was not effective for the treatment of doxorubicin-induced skin necrosis, whereas DHM3 was effective for the treatment of skin necrosis caused by all seven anthracyclines and by the quinone containing antibiotic, mitomycin C.

### Introduction

Cytotoxic drug treatment of human cancer is associated with a spectrum of host organ toxicities. Skin injury resulting from extravasation of necrotizing chemotherapeutic agents accounts for 1–5% of all chemotherapy-related toxicities (1). Extravasation of doxorubicin, a widely used anthracycline antibiotic, is a well-recognized complication of its use with an estimated incidence of 0.5 to 6% (2–4). Mitomycin C and the vinca alkaloids are also necrotizing antitumor drugs that cause tissue injury after extravasation (5, 6). Although infrequent, chemotherapy extravasation may result in significant local and systemic morbidity (7). Clinical experience, uncontrolled clinical trials, and studies in animal models have resulted in different treatment recommendations for chemotherapy extravasation (1, 3–4, 6–10). For example, the Oncology Nursing So-

ciety (9), the most recent edition of a medical oncology textbook (10), and the official manufacturer's product labeling<sup>1</sup> currently recommend corticosteroids to treat anthracycline extravasation. However, there is no proven mechanistic rationale for this practice and the empirical use of corticosteroids has been recently challenged by the results of animal studies (11–14) and clinical experience (6). In spite of extensive laboratory investigation, the molecular mechanism of anthracycline antibiotic cellular toxicity is not fully understood (15). The anthracyclines have been shown to intercalate into DNA (16), form reactive intermediates capable of covalent binding to macromolecules (17) and generate free radical species (18). However, as is true for most of the biological effects of the anthracyclines, it is not clear which of these mechanisms accounts for the skin damage caused by these drugs.

The oxomorpholinyl radical dimers bi(3,5,5-trimethyl-2-oxomorpholin-3-yl) (TM3)<sup>2</sup> and bi(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl) (DHM3) react with doxorubicin or daunorubicin to produce the inactive 7-deoxyaglycone metabolite (19). TM3 was shown to be an effective protectant of systemic anthracycline toxicity (20), and more recently, DHM3 was shown to be effective against acute anthracycline toxicity produced in two animal models (21–22). Because of the anatomic similarities between pig and human skin (23–24), chemotherapy-induced skin injury was studied in a swine model and, in this model, DHM3 was found to be an effective treatment for doxorubicin-induced skin necrosis (22).

In the present study, the capacity of the oxomorpholinyl dimers, TM3 and DHM3, to chemically reduce seven anthracycline antibiotic analogues and mitomycin C is examined. The kinetically determined chemical reactivity of the anthracyclines following reduction with the oxomorpholinyl dimers is shown to correlate with the biological effect of skin injury caused by each anthracycline analogue. Finally, the utility of DHM3 for the prevention of skin injury resulting from anthracycline and mitomycin C antibiotic antitumor agents is shown, and the superiority of DHM3 to that of hydrocortisone for the treatment of doxorubicin-induced skin injury is demonstrated.

### Methods

**Drugs.** Clinical grade doxorubicin HCl, daunorubicin HCl, aclarubicin, menogaril, mitomycin C, vinblastine, mitoxantrone, and bulk powder 5-aminodaunorubicin were obtained from the Drug Synthesis

Address reprint requests to Dr. Averbuch, Department of Neoplastic Diseases, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029. Dr. Bachur's current address is University of Maryland Cancer Center, 22 South Greene Street, Baltimore, MD 21201.

Presented in part at the 77th Annual Meeting of the American Association for Cancer Research, 8 May 1986.

Received for publication 23 October 1986 and in revised form 13 August 1987.

The Journal of Clinical Investigation, Inc.  
Volume 81, January 1988, 142–148

1. Package insert product information (revised December 1985), Adria Laboratories, Columbus, OH.
2. Abbreviations used in this paper: AUC, area under curve; DHM3, bi(3,5-dimethyl-5-hydroxymethyl-2-oxomorpholin-3-yl); TM3, bi(3,5,5-trimethyl-2-oxomorpholin-3-yl).

Branch, Developmental Therapeutics Program, National Cancer Institute, Bethesda, MD. Clinical grade 4-demethoxydaunorubicin and 4'-epidoxorubicin was the generous gift of Adria Laboratories, Columbus, OH. Each drug was reconstituted with sterile water to a final drug concentration of 3.4  $\mu\text{mol/ml}$ . This concentration is equivalent to 2.0 mg/ml doxorubicin HCl; the final concentration recommended by the manufacturer for intravenous administration to patients. DHM3 was synthesized by condensation of 2-amino-2-methyl-1,3-propanediol with ethyl pyruvate followed by a photoreduction reaction to yield the final product, DHM3, a crystalline, white powder. In solution, DHM3 is oxidized by molecular oxygen; therefore, the DHM3 solution was prepared by dissolving the powder in water that had been purged with  $\text{N}_2$  gas for 5 min. Solubilization was facilitated by brief sonication to give a final concentration of 10 mg/ml (31.6  $\mu\text{mol/ml}$ ). The solution was kept cold and protected from air and light. The synthesis of TM3 has been described previously (25). Hydrocortisone sodium succinate (Solu-Cortef; 50 mg/ml, 105  $\mu\text{mol/ml}$ , Upjohn Laboratories, Kalamazoo, MI) was obtained from commercial sources.

**Chemical reaction kinetic determinations.** Oxomorpholinyl dimer, DHM3, (1.38 mg, 4.37  $\mu\text{mol}$ ) was dissolved in 0.5 ml of oxygen-free methanol and quickly transferred via syringe to the spectrophotometric compartment of a two-compartment Pyrex cell with attachment for connection to a vacuum line with an Ultra Torr Union. The solvent was promptly removed under vacuum. Daunorubicin HCl (11.9 mg, 21.1  $\mu\text{mol}$ ) was dissolved in 100 ml of an aqueous solution of Tris (24.2 mg) and Tris HCl (31.6 mg), and 2.6 ml of this solution was introduced into the other compartment of the cell. The solution was freeze (liquid  $\text{N}_2$ )-pump ( $2 \times 10^{-6}$  Torr)-thaw degassed through three cycles, sealed, and placed in a thermostated cell holder at  $10.0 \pm 0.1^\circ\text{C}$  for 20 min before mixing. Full spectra between 320 and 800 nm were recorded every 10 s with a diode array spectrophotometer (8450 UV-visible; Hewlett-Packard Co., Palo Alto, CA) for the first 125 s and then every 20 s. From the absorbance change at 620 nm attributed to the quinone methide intermediate (26) over the first 85 s (50% reaction of daunorubicin), a nonlinear least-squares analysis was used to determine a first order rate constant for bond homolysis of DHM3 ( $k_1$ ) and a first order rate constant ( $k_2$ ) for the production of 7-deoxydaunorubicinone from the quinone methide intermediate. The rate constant ( $k_1$ ) for bond homolysis of DHM3 was also determined at  $25^\circ\text{C}$  by trapping with Ferrin ( $\text{Fe}^{3+}$ -1,10-phenanthroline complex). Using an independently determined value of  $k_1 = 3.4 \times 10^{-3} \text{ s}^{-1}$  for bond homolysis of TM3, the reactivity of TM3 with doxorubicin, daunorubicin, 4-demethoxydaunorubicin, aclarubicin, and menogaril, and the  $k_2$  rate constant for each respective compound in methanol solvent was determined at  $25^\circ\text{C}$  in a similar fashion as previously described (26).

For the measurement of the rate constant ( $k_2$ ) for tautomerization of the quinone methide of 5-iminodaunorubicin, TM3 was replaced by sodium dithionite since the rate of reduction by TM3 was too slow for spectroscopic observation of the quinone methide intermediate. Reactivity of TM3 with mitomycin C was examined in chloroform solvent under anaerobic conditions.

**Animals.** Inbred female weanling miniature white swine weighing approximately 12 kg were obtained from the Veterinary Resources Branch, National Institutes of Health, Bethesda, MD. The development of this strain of swine has been described previously (27). Each animal was housed in a 6  $\times$  4 foot metabolic cage and was fed standard sow chow, 1.5 lb twice daily.

**Anesthesia and antibiotics.** Each animal was anesthetized by intramuscular injections of ketamine (20 mg/kg), xylazine (20 mg/kg), and atropine (1.0 mg). After endotracheal intubation, anesthesia was maintained with a mixture of nitrous oxide, halothane, and oxygen gas. If at any time throughout the experiment the skin lesions appeared to be involved with a superinfection, oxytetracycline (Liquamycin; Pfizer Inc., New York) was administered intramuscularly until there was complete resolution of the infection.

**Drug administration and lesion measurement.** All chemotherapeutic drugs were administered intradermally with a 25-gauge needle along the midlateral aspect of each side of the swine (eight injection

sites per side). After the injection of 1.0 ml of drug solution, (3.4  $\mu\text{mol/ml}$ ) the syringe was removed from the hub, leaving the needle in place. After 15 min, 1.0 ml DHM3 (31.6  $\mu\text{mol/ml}$ ) or hydrocortisone (105  $\mu\text{mol/ml}$ ) was injected through the same needle and the needle was then removed. Alternating adjacent injection sites served as controls, receiving 1.0 ml sterile water instead of DHM3 or hydrocortisone. All lesions were measured by a single observer with metric calipers three times weekly for 2 wk, followed by weekly measurements thereafter. The areas of skin ulceration and induration were estimated by the product of the cross-perpendicular diameters. The total toxicity of drug-induced skin ulceration-vs.-time curve (AUC) was determined by the "cut and weigh" method and was expressed in squared millimeters  $\times$  days (12, 22). Each swine was observed for 8–10 wk.

**Histopathology.** Incisional biopsies were performed on representative lesions 6 and 20 d after doxorubicin intradermal injections, and 9 and 24 d after DHM3 injections. Upon termination of the experiment on day 71, incisional biopsies were performed on representative healing lesions that had received water, DHM3, or hydrocortisone treatment after doxorubicin injection. Samples were placed in 10% buffered formalin and processed for examination by standard light microscopy (Pathco, Inc., Potomac, MD).


**Statistical analysis.** The skin toxicity data were analyzed by the two-tailed *t* test for independent means, and linear regression for toxicity versus  $k_2$  was determined by the least squares method (28).

## Results

**Chemical reactivity of oxomorpholinyl dimers with anthracycline antibiotics and mitomycin C.** When a 10-fold excess of DHM3 was added to a solution of 200  $\mu\text{M}$  daunorubicin in buffered (pH 8.0), oxygen-free water at  $10^\circ\text{C}$  there was a rapid and irreversible formation of the aglycone, 7-deoxydaunorubicinone. This reaction is shown in Fig. 1 where the end-product 7-deoxydaunorubicinone, the structure of which was established by spectral and chromatographic comparison with an authentic sample, is the aglycone derived from daunorubicin (compound B). As determined from experimentally derived absorbance data at  $10^\circ\text{C}$ , the reaction followed consecutive first-order kinetics with a rate constant ( $k_1$ ) of  $6 \times 10^{-4} \text{ s}^{-1}$  for bond homolysis of DHM3 and a rate constant ( $k_2$ ) of  $2 \times 10^{-2} \text{ s}^{-1}$  for the production of 7-deoxydaunorubicinone from a quinone methide intermediate (Fig. 1). At  $25^\circ\text{C}$ ,  $k_1 = 6 \times 10^{-3} \text{ s}^{-1}$ . The rate constant ( $k_1$ ), which determines the rate of production of the quinone methide intermediate, indicated that DHM3 has approximately the same reactivity with daunorubicin in water as does the related oxomorpholinyl dimer TM3 in methanol solvent ( $k_1 = 3.4 \times 10^{-3} \text{ s}^{-1}$ , at  $25^\circ\text{C}$ , [26]). Thus, TM3 was used to study the reactivity of the oxomorpholinyl dimers with seven different anthracycline analogues. As shown in Fig. 1, specific substitutions on the anthracycline molecule result in different rate constants ( $k_2$ ) for the production of the aglycone from each respective analogue through the quinone methide intermediate. The rate constants ( $k_2$ ) ranged from  $2 \times 10^{-2} \text{ s}^{-1}$  for 5-iminodaunorubicin to  $8.0 \times 10^{-4} \text{ s}^{-1}$  for aclarubicin.

When TM3 was added to a chloroform solution containing mitomycin C, spectroscopic analysis showed an efficient reaction as indicated by the disappearance of the mitomycin C absorption at 358 nm and increase in absorbance at 312 nm with a sharp isosbestic point at 324 nm (data not shown).

**Drug-induced skin necrosis in swine.** The intradermal injection of doxorubicin in swine produced a predictable and reproducible skin ulceration that has been fully described previously (22).



Compound	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	R <sub>5</sub>	k <sub>2</sub> (s <sup>-1</sup> )
A. Doxorubicin	COCH <sub>2</sub> OH	OCH <sub>3</sub>	O	H <sub>2</sub>	Daunosamine	1.1 × 10 <sup>-2</sup>
B. Daunorubicin	COCH <sub>3</sub>	OCH <sub>3</sub>	O	H <sub>2</sub>	Daunosamine	1.3 × 10 <sup>-2</sup>
C. 4-Demethoxydaunorubicin	COCH <sub>3</sub>	H	O	H <sub>2</sub>	Daunosamine	9.0 × 10 <sup>-3</sup>
D. 4'-Epidoxorubicin	COCHOH	OCH <sub>3</sub>	O	H <sub>2</sub>	4-Epidaunosamine	1.0 × 10 <sup>-2*</sup>
E. 5-Iminodaunorubicin	COCH <sub>3</sub>	OCH <sub>3</sub>	NH	H <sub>2</sub>	Daunosamine	2 × 10 <sup>-2‡</sup>
F. Aclarubicin	C <sub>2</sub> H <sub>5</sub>	OH	O	COOCH <sub>3</sub>	Rhodosamine-Deoxyfucose-L-Cinerulose	8.0 × 10 <sup>-4</sup>
G. Menogaril	(7-Con-O-methylnogarol)					2.5 × 10 <sup>-3</sup>

**Figure 1.** In vitro reaction of anthracycline antibiotics with the substituted oxomorpholinyl dimers, TM3 and DHM3, to form the 7-deoxyanthracycline aglycone. The anthracycline analogues were dissolved in methanol and reacted with TM3 under anaerobic conditions as described in Methods. The rate constant,  $k_2$ , describes the

tautomerization of the quinone methide intermediate to the aglycone product. \* The rate constant for 4'-epidoxorubicin was not measured, but assumed equal to that of doxorubicin (34). ‡ The rate constant for 5-iminodaunorubicin was measured by replacing TM3 with sodium dithionite in the reaction.

Intradermal injection of 1.0 ml (3.4  $\mu\text{mol/ml}$ ) of several cytotoxic antitumor agents resulted in skin injury similar to doxorubicin, but the extent and time course of the injury varied with the drug (Table I). Mitomycin C caused the greatest skin injury (40% greater than for doxorubicin) while the anthracycline analogues aclarubicin and menogaril caused similar lesions that were one-third as severe as doxorubicin.

Since the rate constants ( $k_2$ ) reflect the reactivity of the quinone methide intermediate for each anthracycline analogue and since this intermediate has been proposed as a species capable of covalently binding to biological macromolecules (26), we compared the rate constant ( $k_2$ ) to the total toxicity (Table I) for each of the anthracycline analogues studied. As shown in Fig. 2, the reactivity of each analogue, determined in a defined in vitro chemical system, correlated with the degree of in vivo skin toxicity caused by that analogue.

DHM3 effectively reduced the skin necrosis caused by the anthracycline analogues and mitomycin C (Table I). Skin toxicity caused by vinblastine or mitoxantrone was not reduced by DHM3.

The effect of several pharmacological interventions on the course of the doxorubicin-induced skin injury is shown in Fig. 3 and Table II. When DHM3 (31.6  $\mu\text{mol}$ ) was injected into the same site 15 min after doxorubicin (3.4  $\mu\text{mol}$ ), the peak area of the ulcer was reduced 77%, the total toxicity was reduced 95%,

**Table I.** Protection against Chemotherapy-induced Skin Injury

Drug	Total toxicity ( $\text{mm}^2 \times d$ )		
	H <sub>2</sub> O	DHM3	Difference
			%
Mitomycin C	22,271	9,252	-58
Doxorubicin	16,014	4,646	-71
Daunorubicin	14,517	5,310	-63
4-Demethoxydaunorubicin	9,994	2,451	-75
4'-Epidoxorubicin	12,564	2,031	-84
5-Iminodaunorubicin	16,712	6,450	-61
Aclarubicin	5,900	1,742	-70
Menogaril	5,265	2,087	-60
Vinblastine	12,946	16,101	+24
Mitoxantrone	14,187	16,063	+13

After the intradermal injection of 1.0 ml chemotherapeutic drug (3.4  $\mu\text{mol}$ ), either 1.0 ml sterile H<sub>2</sub>O or DHM3 (31.6  $\mu\text{mol}$ ) was injected through the same needle 15 min later. All lesions were measured three times weekly for 2 wk and then weekly. The area of skin ulceration was estimated by the product of the cross-perpendicular diameters. The total toxicity is the AUC for the skin ulceration vs. time curve. Data are the mean of two experiments.




Figure 2. Correlation between skin toxicity after intradermal anthracycline injection in vivo and the reactivity of anthracyclines in vitro. The curve was derived from data presented in Table I and Fig. 1. The letters (A-G) correspond to the anthracycline analogues shown in Fig. 1. Each data point represents the mean of two skin ulceration sites.  $r^2 = 0.85$ ,  $P < 0.005$




Figure 3. Time course of doxorubicin-induced skin injury. (A) Skin ulceration. (B) Skin induration. Following the intradermal injection of doxorubicin,  $3.4 \mu\text{mol}$  in  $1.0 \text{ ml}$  sterile  $\text{H}_2\text{O}$ , each site received  $1.0 \text{ ml}$  of either sterile  $\text{H}_2\text{O}$ , hydrocortisone sodium succinate ( $105 \mu\text{mol}$ ), or DHM3 ( $31.6 \mu\text{mol}$ ) as described in Methods. Each lesion area was estimated by the cross-perpendicular diameters. Each point represents the mean  $\pm$  SD of triplicate experiments. \*  $P < 0.05$ , determined by the two-tailed  $t$  test for independent means.

Table II. Protection against Doxorubicin-induced Skin Injury

	$\text{H}_2\text{O}$	Hydrocortisone	DHM3
Maximal lesion size ( $\text{mm}^2$ )			
Ulcer	159	234	36*
Induration	1048	1169	714
Healing time (d)			
Ulcer	>70	>70	35*
Induration	>70	>70	50*
Total toxicity ( $\text{mm}^2 \times \text{d}$ )			
Ulcer	10,742	12,726	570*
Induration	45,536	45,992	14,800*


After the intradermal injection of  $1.0 \text{ ml}$  doxorubicin ( $3.4 \mu\text{mol}$ ),  $1.0 \text{ ml}$  sterile water, hydrocortisone sodium succinate ( $105 \mu\text{mol}$ ), or DHM3 ( $31.6 \mu\text{mol}$ ) was injected through the same needle  $15 \text{ min}$  later. All lesions were measured three times weekly for  $2 \text{ wk}$  and then weekly. The areas of skin ulceration and induration were estimated by the product of the cross-perpendicular diameters. The total toxicity is the AUC for the skin ulceration vs. time curve. Data are the mean of three experiments.

\*  $P$  value  $< 0.025$  compared to  $\text{H}_2\text{O}$  treatment.

and healing was completed in less than one-half the time when compared to controls. In contrast, injection of hydrocortisone sodium succinate ( $105 \mu\text{mol}$ )  $15 \text{ min}$  after doxorubicin failed to provide any protection against subsequent development of skin ulceration. In fact, hydrocortisone treatment appeared to worsen the extent of skin injury; although this was statistically significant for only one time point (day 12, Fig. 3 A). The effect of DHM3 and hydrocortisone on the surrounding skin induration paralleled that observed for the ulceration (Fig. 3 B, Table II).

**Histopathological studies.** The acute and chronic histopathological appearance of doxorubicin-induced skin injury was determined from representative biopsies.  $6 \text{ d}$  after intradermal injection of doxorubicin, microscopic examination of an incisional biopsy of the lesion showed focal epidermal necrosis with early ulceration (Fig. 4 A). There was neutrophilic infiltration of the necrotic epidermis and underlying superficial dermis with moderate dermal vascular congestion. At  $20 \text{ d}$ , tissue necrosis was more extensive involving the full thickness of dermis, subcutaneous fat, and muscle (Fig. 4 B). There was partial reepithelialization of the ulceration with focal residual ulcer containing overlying crusting. Lymphocytic infiltration was in the superficial dermis and neutrophilic infiltration was in the dermis beneath the residual ulceration. The intradermal injection of DHM3 alone caused no macroscopic skin injury. Microscopic examination of incisional biopsies of DHM3 injection sites taken  $9$  and  $24 \text{ d}$  after intradermal injection showed normal appearing epidermis, dermis, and subdermal structures (Fig. 4 D).

At the termination of the experiment,  $10 \text{ wk}$  after doxorubicin injection, histopathological examination of biopsies from the doxorubicin injection sites treated with water or hydrocortisone showed scar tissue replacing the full dermal thickness (Fig. 4 C, E). In contrast, the doxorubicin injection site treated with DHM3 showed minimal deep dermal fibrosis with preservation of normal collagen pattern throughout most of the dermis (Fig. 4 F).



**Figure 4.** Hematoxylin-eosin stained microscopic sections from skin biopsies. (A) Doxorubicin injection site on day 6, showing necrosis of epidermis, neutrophils in necrotic epidermis and subjacent dermis, and congested dermal blood vessels ( $\times 130$ ). (B) Doxorubicin injection site on day 20, showing extensive necrosis of the full thickness of dermis and subcutaneous fat with reepithelialization of most of the ulcer ( $\times 11.5$ ). (C) Doxorubicin injection site (treated with H<sub>2</sub>O) on day 71, showing extensive dermal fibrosis and fatty infiltration ( $\times 11.5$ ). (D) DHM3 injection site on day 24, showing normal epidermis and dermis ( $\times 54$ ). (E) Doxorubicin injection site (treated with hydrocortisone) on day 71, showing extensive dermal fibrosis and fatty infiltration ( $\times 11.5$ ). (F) Doxorubicin injection site (treated with DHM3) on day 71, showing minimal fibrosis in the deep dermis ( $\times 38$ ).

## Discussion

Our study demonstrates the utility of the swine model for examining chemotherapy-induced skin injury wherein early and late histopathological features of doxorubicin skin injury in the pig are similar to those described from human skin biopsies (7, 29). It follows that the results of various pharmacologic interventions designed to reduce or protect against anti-tumor drug-induced skin injury in the swine model would reliably predict the effects of these interventions in humans.

In a well-defined *in vitro* chemical system the oxomorpholinyl radical dimers, TM3 and DHM3, were potent reducing agents of the anthracycline antibiotic, daunorubicin, resulting in the production of the pharmacologically inactive 7-deoxydaunorubicinone. This finding predicted that these radical dimers could be used *in vivo* to inactivate the parent anthracyclines and thereby ameliorate acute toxicity. As predicted from this *in vitro* chemical reaction, where a 10-fold molar excess of TM3 reductively inactivated anthracyclines to deoxyglycone metabolites, a 10-fold excess of DHM3 was an effective antidote for anthracycline-induced skin necrosis *in vivo*. Whereas the skin was not analyzed for doxorubicin and its metabolites, previous studies from this laboratory have shown that DHM3 caused a decrease in parent doxorubicin and an increase in 7-deoxydoxorubicinone concentrations *in vivo* (21). The observation of mitomycin C reactivity with TM3 led to the postulate that these compounds would also interact *in vivo* and our results confirmed this prediction. In contrast, there is no chemical basis for chemical reactivity of the oxomorpholinyl dimers with the vinca alkaloids nor with the substituted anthracenediones; and, as predicted, there was no DHM3 protection of vinblastine nor mitoxantrone-induced skin necrosis.

The current recommendation for the use of glucocorticoids to treat anthracycline-induced skin necrosis is based on one clinical study (3) and conflicting data from several animal studies (8, 11–14). However, there is no mechanistic rationale for the corticosteroids to be an anthracycline antidote. Even though we observed moderate polymorphonuclear infiltration of the dermis 6 d following the injection of doxorubicin, it is likely that this represents an acute response reaction rather than a cause of tissue injury. By directly comparing the effect of hydrocortisone to controls, we were unable to show any protective activity of this glucocorticoid against anthracycline-induced skin necrosis.

Our data provide additional insight into the mechanism of anthracycline-induced tissue injury. While the anthracyclines have been shown to intercalate DNA base pairs, and to inhibit DNA and RNA synthesis (15); there are anthracycline analogs that appear to act by different mechanisms (30). In addition, the anthracycline antibiotics are also capable of undergoing enzymatic reduction to form free radical species which may then cause damage to cellular macromolecules (18, 31–33). At the present time, there is no evidence that either DNA intercalation or free radical generation is directly responsible for the tissue injury resulting from anthracycline extravasation.

Since the anthracyclines and mitomycin C are capable of undergoing bioreductive activation (15, 34), the formation and reaction of quinone methide intermediates has been proposed as an important process in drug mechanism (35). The measured rate constant ( $k_2$ ) for the tautomerization of the quinone methide intermediate formed from the reduction of each

anthracycline analogue is a measure of the nucleophilicity of the respective quinone methide intermediate. The rate constants ( $k_2$ ) measured in this study established an order of quinone methide nucleophilicity and show a strong correlation with the total toxicity observed in the pig skin necrosis model (Fig. 2). This correlation is best shown in the case of 5-imino-daunorubicin, a compound not easily reduced to produce oxygen free radicals (33), but one that forms the most reactive quinone methide intermediate and was also found to be the most toxic analogue in skin. In contrast, the least reactive quinone methides result from reduction of menogaril and aclarubicin, and these compounds were the least toxic compounds in skin. All of which suggests that the bioreductively formed quinone methide nucleophilic reactivity with biological macromolecules is the basis of the anthracycline cellular damage.

Correlation of skin toxicity with anthracycline quinone methide reactivity must be rationalized with the antidotal activity of DHM3 that forces rapid formation of the quinone methide. The antidotal activity of DHM3 most likely results from reductive glycosidic cleavage in a compartment (such as the extracellular space) where the quinone methide is presumably innocuous, being formed before association of the anthracycline with a critical intracellular macromolecule. Formation of the quinone methide at these locations would simply yield the pharmacologically inactive 7-deoxyglycone anthracycline (21). Whether the nucleophilicity of the quinone methide intermediate within the intracellular compartment is responsible for other toxicity or antitumor action of the anthracycline antibiotics is the subject of current investigation.

## Acknowledgments

We thank Dr. Donna Mathews and Dr. James Harwell of the Veterinary Resources Branch, Division of Research Services, NIH, for excellent veterinary support services and we thank Dr. Anthony D. Barone for investigation of TM3 reactivity with mitomycin C. We also thank Raymond Bork for technical assistance, Dr. Jerry Collins for statistical advice, Dr. Angelo Russo for review of the manuscript, and Beverly Sisco for preparation of this manuscript.

This work was supported in part by the National Cancer Institute, grant CA-24665.

## References

1. Ignoffo, R. J., and M. A. Friedman. 1980. Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. *Cancer Treat. Rev.* 7:17–27.
2. Wang, J. J., E. Cortes, L. F. Sinks, and J. F. Holland. 1971. Therapeutic effect and toxicity of adriamycin in patients with neoplastic diseases. *Cancer.* 38:837–843.
3. Barlock, A. L., D. M. Howser, and S. M. Hubbard. 1979. Nursing management of adriamycin extravasation. *Am. J. Nurs.* 79:94–96.
4. Larson, D. L. 1982. Treatment of tissue extravasation by antitumor agents. *Cancer.* 49:1796–1799.
5. Argenta, L. C., and E. K. Manders. 1983. Mitomycin C extravasation injuries. *Cancer.* 51:1080–1082.
6. Larson, D. L. 1985. What is the appropriate management of tissue extravasation by antitumor agents? *Plast. Reconstr. Surg.* 75:397–402.
7. Linder, R. M., J. Upton, and R. Osteen. 1983. Management of extensive doxorubicin hydrochloride extravasation injuries. *J. Hand Surg.* 8:32–38.

8. Harwood, K. V., and J. Aisner. 1984. Treatment of chemotherapy extravasation: Current status. *Cancer Treat. Rep.* 68:939-945.
9. Oncology Nursing Society. 1984. Cancer chemotherapy. Guidelines and recommendations for nursing education and practice. Pittsburgh. 11-17.
10. Hubbard, S. M., and C. A. Seipp. 1985. Administration of cancer treatments: Practical guide for physicians and oncology nurses. In *Cancer. Principles and practice of oncology*. V. DeVita, S. Hellman, and S. Rosenberg, editors. J. B. Lippincott Co., Philadelphia. 2189-2222.
11. Seigel, D. M., S. N. Giri, R. M. Scheinholtz, and L. W. Schwartz. 1980. Characteristics and effect of antiinflammatory drugs on adriamycin-induced inflammation in the mouse paw. *Inflammation*. 4:233-248.
12. Dorr, R. T., D. S. Alberts, and H. S. G. Chen. 1980. The limited role of corticosteroid ameliorating experimental doxorubicin skin toxicity in the mouse. *Cancer Chemother. Pharmacol.* 5:17-20.
13. Upton, P. G., K. T. Yamaguchi, S. Myers, T. P. Kidwell, and R. J. Anderson. 1986. Effects of antioxidants and hyperbaric oxygen in ameliorating experimental doxorubicin skin toxicity in the rat. *Cancer Treat. Rep.* 70:503-507.
14. Loth, T. S., and W. W. Eversmann Jr. 1986. Treatment methods for extravasations of chemotherapeutic agents. A comparative study. *J. Hand Surg.* 11A:388-396.
15. Gianni, L., B. J. Corden, and C. E. Myers. 1983. The biochemical basis of anthracycline toxicity and antitumor action. *Rev. Biochem. Toxicol.* 5:1-82.
16. Arcamone, F. 1981. Doxorubicin anticancer antibiotics. Academic Press, Inc., New York. pp. 1-354.
17. Moore, H. W. 1977. Bioactivation as a model for drug design. Bioreductive alkylation. *Science (Wash. DC)*. 197:527-532.
18. Bachur, N. R., M. V. Gee, and R. D. Friedman. 1982. Nuclear catalyzed antibiotic free radical formation. *Cancer Res.* 42:1078-1081.
19. Barone, A. D., R. F. Atkinson, D. L. Wharry, and T. H. Koch. 1981. In vitro reactivity of the meso and dl dimers of the 3,5,5-trimethyl-2-oxomorpholin-3-yl radical with adriamycin and daunomycin. *J. Am. Chem. Soc.* 103:1606-1607.
20. Banks, A. R., T. Jones, T. H. Koch, R. D. Friedman, and N. R. Bachur. 1983. Prevention of Adriamycin toxicity. *Cancer Chemother. Pharmacol.* 11:91-93.
21. Averbuch, S. D., G. Gaudiano, T. H. Koch, and N. R. Bachur. 1985. Radical dimer toxicity and improved therapeutic index of adriamycin in tumor-bearing mice. *Cancer Res.* 45:6200-6204.
22. Averbuch, S. D., G. Gaudiano, T. H. Koch, and N. R. Bachur. 1986. Doxorubicin-induced skin necrosis in the swine model. Protection with a novel radical dimer. *J. Clin. Oncol.* 4:88-94.
23. Montagna, W., and J. S. Yun. 1964. The skin of the domestic pig. *J. Invest. Dermatol.* 43:11-21.
24. Bartek, M. J., J. A. LaBudde, and H. I. Maibach. 1972. Skin permeability in vivo. Comparison in rat, rabbit, pig, and man. *J. Invest. Dermatol.* 58:114-123.
25. Bennett, R., D. L. Wharry, and T. H. Koch. 1980. Formation kinetics of an amino carboxy type merostabilized free radical. *J. Am. Chem. Soc.* 102:2345-2359.
26. Kleyer, D. L., and T. H. Koch. 1984. Mechanistic investigation of reduction of daunomycin and 7-deoxydaunomycinone with bi(3,5,5-trimethyl-2-oxomorpholin-3-yl). *J. Am. Chem. Soc.* 106:2380-2387.
27. Sachs, D. H., G. Leight, J. Cone, S. Schwarz, L. Stuart, and S. Rosenberg. 1976. Transplantation in miniature swine. *Transplantation*. 22:559-567.
28. Snedecor, G. W., and W. G. Cochran. 1967. *Statistical Methods*. The Iowa State University Press. 32-65, 135-171.
29. Rudolph, R., R. S. Stein, and R. A. Pattillo. 1976. Skin ulcers due to adriamycin. *Cancer*. 38:1087-1094.
30. Abdella, B. R. J., and J. Fisher. 1985. A chemical perspective on the anthracycline antitumor antibiotics. *Environ. Health Perspec.* 64:3-18.
31. Berlin, V., and W. W. Haseltine. 1981. Reduction of adriamycin to a semiquinone by NADPH: Cytochrome P-450 reduction produces DNA cleavage in a reaction mediated by O<sub>2</sub>. *J. Biol. Chem.* 256:4747-4756.
32. Mimnaugh, E. G., M. A. Trush, E. Ginsburg, and T. E. Gram. 1982. Differential effects of anthracycline drugs on rat heart and liver microsomal NADPH-dependent lipid peroxidation. *Cancer Res.* 42:3574-3582.
33. Lown, J. W., H. H. Chen, J. A. Plambeck, and E. M. Acton. 1982. Further studies on reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects. *Biochem. Pharmacol.* 31:575-581.
34. Pan, S., T. Iracki, and N. R. Bachur. 1986. DNA alkylation by enzyme-activated mitomycin C. *Mol. Pharmacol.* 29:622-628.
35. Fisher, J., B. R. J. Abdella, and K. E. McLane. 1985. Anthracycline antibiotic reduction by spinach ferredoxin-NADP<sup>+</sup> reductase and ferredoxin. *Biochemistry*. 24:3562-3571.